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Despite an improved understanding of the genetic background and the
pathomechanisms of amyotrophic lateral sclerosis (ALS) no novel disease-modifying
therapies have been successfully implemented in clinical routine. Riluzole still remains
the only clinically approved substance in human ALS treatment with limited efficacy.
We have previously identified pharmacological rho kinase (ROCK) inhibitors as orally
applicable substances in SOD1.G93A transgenic ALS mice (SOD1G93A), which are able
to extend survival time and improve motor function after presymptomatic treatment.
Here, we have evaluated the therapeutic effect of the orally administered ROCK inhibitor
Fasudil starting at a symptomatic disease stage, more realistically reflecting the clinical
situation. Oral Fasudil treatment was initiated at a symptomatic stage at 80 days of life
(d80) with 30 or 100mg/kg body weight in both female and male mice. While baseline
neurological scoring and survival were not influenced, Fasudil significantly improved
motor behavior in male mice. Spinal cord pathology of motoneurons (MN) and infiltrating
microglial cells (MG) at disease end-stage were not significantly modified. Although
treatment after symptom onset was less potent than treatment in asymptomatic animals,
our study shows the therapeutic benefits of this well-tolerated substance, which is
already in clinical use for other indications.
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INTRODUCTION
Amyotrophic lateral sclerosis (ALS) is a devastating neuromuscular disease, which is characterized
by the degeneration of the first and second motoneuron (MN) resulting in severe muscle weakness.
Within a few years after initial diagnosis death is often caused by global respiratory insufficiency.
The neurodegenerative process in ALS comprises the loss of spinal MNs and their axons as
well as the destruction of neuromuscular junctions, where distinct pathological changes can be
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observed first. Some authors thus consider ALS as a distal
axonopathy (Moloney et al., 2014). The mechanisms of ALS
pathogenesis are multifactorial and include protein aggregation,
oxidative stress, excitotoxicity, mitochondrial dysfunction,
disturbances in RNAmetabolism, and impaired axonal transport
(Robberecht and Philips, 2013; Peters et al., 2015). Moreover,
microglia (MG), astroglia, and oligodendroglia may determine
the onset and the dynamics of disease progression (Philips and
Robberecht, 2011; Brites and Vaz, 2014).
Recently, the spectrum of human familial ALS forms has been
broadened by the discovery of several novel gene mutations
(Vucic et al., 2014). While genetic mutations in the human
superoxide dismutase 1 (SOD1) were the first to be identified
(Rosen et al., 1993), further pathogenic mutations have also
been found in Fused in sarcoma (FUS), TAR DNA-binding
protein 43 (TDP-43), or in the gene C9orf72 (Turner et al.,
2013). Some of these familial ALS gene mutations have been
employed to establish new transgenic mouse models of ALS.
Because of its close recapitulation of the progression of human
disease, however, the SOD1G93A mouse model of ALS has
evolved as a standard model for the evaluation of therapeutic
effects in preclinical studies (Turner and Talbot, 2008). Several
neuroprotective agents have been found to delay the onset of
clinical disease and to prolong the disease course in ALS mice,
but only the glutamate antagonist Riluzole was successfully
transferred into clinical practice (Benatar, 2007). Unfortunately,
Riluzole has only limited effects in human ALS patients
prolonging life only by a few months (Stewart et al., 2001).
Therefore, the need for more potent disease-modifying therapies
of ALS remains.
Rho kinases (ROCK) are serine/threonine kinases that
are known to modulate cytoskeletal structure through
phosphorylation of LIM kinases, myosin light chain or the
ezrin/radixin/moesin protein complex (Tönges et al., 2011).
Fasudil, 1-(5-Isoquinolinylsulfonyl) homopiperazine, belongs
to the isoquinoline series of ROCK inhibitors and contains as
structural feature an isoquinoline and homopiperazine ring,
which are connected by a sulphonyl group. The inhibition of
ROCK is of competitive type and takes place at the ATP binding
site (Jacobs et al., 2006). Fasudil is one of the most thoroughly
evaluated ROCK inhibitors and has been studied in various
models of neurodegenerative disease (Bowerman et al., 2012;
Tönges et al., 2012, 2014; Li et al., 2013; Takata et al., 2013; Zhao
Y. F. et al., 2015; Tatenhorst et al., 2016). In these, a good oral
bioavailability and effective penetration of the blood brain barrier
were shown (Hattori et al., 2004; Takata et al., 2013; Tönges et al.,
2014). More importantly, our group and others have recently
Abbreviations: ANOVA, analysis of variance; ALS, amyotrophic lateral sclerosis;
CMAP, compound muscle action potential; CNS, central nervous system; d70, day
of life 70; d80, day of life 80; d100, day of life 100; DML, distal motor latency;
Fas30, Fasudil 30mg/kg body weight; Fas100, Fasudil 100mg/kg body weight;
FUS, Fused in sarcoma; MN, motoneuron; MG, microglial cells; NCV, Nerve
conduction velocity; PBS, phosphate-buffered solution; ROCK, rho-associated
kinase; SMA, spinal muscular atrophy; SOD1, superoxide dismutase 1; SOD1G93A,
superoxide dismutase 1 G93A transgenic; SOD1WT, superoxide dismutase 1 wild
type; TDP-43, TAR DNA-binding protein 43; Veh, vehicle (drinking water without
supplementation).
demonstrated that inhibition of ROCK with pharmacological
small molecule inhibitors strongly fosters the regenerative
response in the lesioned central nervous system (CNS; Lingor
et al., 2008; Planchamp et al., 2008; Bermel et al., 2009) and
can activate intracellular neuroprotective and anti-apoptotic
signaling cascades such as the Akt pathway (Tönges et al., 2012;
Takata et al., 2013; Zhao Y. et al., 2015). In SOD1G93A ALS mice
ROCK activity was shown to be increased and phosphorylated
Akt levels were decreased (Takata et al., 2013; Golko-Perez et al.,
2016). Treatment with the ROCK inhibitor Fasudil strengthened
Akt signaling and led to increased survival of motoneurons
if treatment was started presymptomatically (Takata et al.,
2013). Furthermore, we could recently demonstrate in studies
in SOD1G93A ALS mice that the presymptomatic use of the
small-molecule ROCK inhibitor Fasudil is able to extend survival
time and improve motor function (Tönges et al., 2014). Protein
levels of ROCK2 as well as of its downstream targets LIMK1 and
cofilin2 have been shown to be significantly increased in skeletal
muscle biopsies from ALS patients compared to age-matched
controls (Conti et al., 2014). Interestingly, phosphorylated Akt
levels were found to be decreased in muscle biopsies of ALS
patients in comparison to their control counterparts (Léger et al.,
2006).
Here, we have now conducted an oral treatment study with
the ROCK inhibitor Fasudil in symptomatic SOD1G93A mice,
because in clinical reality treatment initiation before symptom
onset will hardly be feasible for sporadic ALS cases. As starting
point for treatment initiation we have chosen day of life 80 (d80)
based on first signs of disease in neurological examination and in
electrophysiological measurements. Fasudil was applied in two
different dosages in both male and female animals. The clinical
disease course and performance in behavioral tests was closely
monitored and was compared to the immunohistological analysis
of the spinal cord MN survival and MG infiltration at end-stage.
MATERIALS AND METHODS
Animal Housing, Breeding, Genotyping,
and Application of Fasudil
All animal experiments were carried out according to
the regulations of the local animal research council
(Niedersächsisches Landesamt für Verbraucherschutz und
Lebensmittelsicherheit, Oldenburg, Germany) and legislation
of the State of Lower Saxony, Germany. High-copy number
B6/SJL-Tg(SOD1 G93A)1Gur/J (Gurney et al., 1994) were
obtained from Jackson Labs (Stock Number 002726; Bar
Harbor, USA). The colony was maintained by crossing B6/SJL
males harboring the transgene with wild-type B6/SJL females.
Housing of animals was performed under a 12 h light/12 h dark
cycle with free access to food and water. For genotyping, tail
biopsies of 21-day-old mice were subjected to a standardized
PCR protocol (Jackson Labs). Probe sequences were: hSOD1-
forward, CATCAGCCCTAATCCATCTGA; hSOD1-reverse,
CGCGACTAACAATCAAAGTGA; both SOD1G93A female and
male mice were used in the experiments. Fasudil (“F-4660,” LC
Labs, Woburn, Massachusetts, USA) was orally administered at
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a concentration of 30 mg/kg body weight per day (subsequently
termed as Fas30) or at a concentration of 100 mg/kg body weight
per day (Fas100) in drinking water. Control groups received
drinking water without supplementation (Veh).
Electrophysiological Analysis
Nerve conduction velocities (NCV) and compound muscle
action potentials (CMAP) were determined as previously
described (Zielasek et al., 1996). Time points of analysis were 70
and 100 days of age. Briefly, mice were anesthetized using an
intraperitoneal injection of ketamine (100mg/kg body weight)
and xylazine (8mg/kg body weight). CMAP and distal motor
latencies (DML) were recorded from the intrinsic foot muscles
using steel electrodes. NCV were calculated automatically based
on the two stimulation sites.
Clinical and Behavioral Animal Testing
Experimental Groups
At d80, which was considered as a definitive symptomatic stage
based on the preceding electrophysiological analysis, mice were
allocated to three treatment groups (Fas30, Fas100 andVeh) in an
observer-blinded fashion. Groups were constituted to minimize
inter-group variability by matching of animals with respect to
body weight and litter.
Monitoring of Disease
Neurological score
Neurological scores were assessed every three days for each
mouse from 80 days of age. The neurological score employed a
scale of 0–4 which had been developed in ALSmouse trials before
(Weydt et al., 2003). Score criteria used to assign each score level
were:
4: Full extension of hind legs away from lateral midline when
mouse is suspended by its tail, and mouse can hold this for 2 s,
suspended 2–3 times.
3: Collapse or partial collapse of leg extension toward
lateral midline (weakness) or trembling of hind legs during tail
suspension. Score criterion 3 is defined as clinical disease onset.
2: Toes curl under at least twice during walking of 10 cm, or
any part of foot is dragging along cage bottom/table. From this
score criterion on food pellets are left on bedding and water is
additionally placed in a well on the bedding.
1: Rigid paralysis or minimal joint movement, foot not being
used for forward motion.
0: Mouse cannot right itself within 30 s from either side or
have lost 25% of their maximum body weight. This indicated
fulfillment of the experimental termination criteria and mice
were sacrificed.
Body weight
Body weight is a sensitive indicator of any malaise that might
result from chronic drug treatment and ofmotor impairment that
occurs during disease progression. Body weight measurements
were recorded every 3 days for each animal beginning at 80 days
of age.
Survival
Date and cause of death were recorded for each mouse. For
ethical reasons, animals are closely monitored and sacrificed
as moribund prior to actual death using criteria for severe
illness. To determine duration of survival reliably and ethically,
the moribund state, defined as the inability of mice to right
themselves 30 s after being placed on a side or have lost 25% of
their maximum body weight (a neurological score of 0) was used.
The moribund mice were scored as “dead,” and were sacrificed.
Rotarod test
The rotarod apparatus (Ugo Basile, Comerio, Italy) was used to
measure motor coordination, balance, and motor learning ability
(Miana-Mena et al., 2005; Crawley, 2008). A good performance
requires a high degree of sensorimotor coordination. It consists
of a computer-controlled motor-driven rotating spindle and five
lanes for five mice. Falls of the mice are detected automatically by
pressure on a plastic plate at the bottom. After training for three
times at a constant speed of 15 rpm and for the duration of 180 s,
mice were tested every 3 days beginning on d80 and the time for
which an animal can remain on the rotating rod is measured. For
animals which could not remain 180 s on the rotarod, a second
and third trial with a break of 10 min was applied. Means of
all trials of each animal were included in the statistical analysis.
The time of 180 s is chosen as an arbitrary cut-off time because
the majority of significant differences in motor coordination are
detected in this time frame.
Immunohistochemistry and Quantification
of Motoneurons and Microglia
Animals were killed by CO2 insuﬄation at disease end-stage
in accordance with the local guidelines. Thereafter, they were
transcardially perfused with PBS solution followed by 4%
paraformaldehyde. Spinal cords were removed as described
before (Günther et al., 2012) and were post-fixed for 2 h in 4%
paraformaldehyde. Thereafter, the tissue was dehydrated in 30%
sucrose overnight and kept at −20◦C until further processing.
Coronal sections of the lumbar spinal cord (L3–L6) with a
thickness of 20 µm were prepared using a cryostat (Leica,
Wetzlar, Germany) and collected on gelatine-coated glass slides.
Spinal cord sections were immunolabeled with the primary
antibodies (anti-ChAT, 1:100, Millipore; anti-Iba1, 1:500,
WAKO, Osaka, Japan) and subsequently with the respective
secondary antibodies (Cy3 anti-goat or Cy2/Dylight anti-rabbit;
both Dianova).
In order to quantify MN numbers in the ventral horn of
coronal cryosections from the lumbar spinal cord, cells in the
ventral horn were counted as MN if they had a clearly identifiable
nucleolus, were at least 200 µm2 in size and were ChAT-positive.
At least ten sections per mouse spinal cord including both ventral
horns being at least 100 µm apart over a length of at least 1000
µm from the lumbar spinal cord were counted. In the treatment
groups a total number of nine mice were analyzed from vehicle
(n = 3), Fas30 (n = 3) and Fas100 (n = 3). Microgliosis was
evaluated by the quantification of Iba1 positive cells in the ventral
horn of lumbar spinal cord sections. In contrast to the MN
analysis MGwere not confined to ventral horn region. Therefore,
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the ventral horn area was measured and Iba1 positive cells were
manually counted and plotted as cell numbers per 0.2 mm2. A
total number of nine mice each gender was analyzed from vehicle
(n= 3), Fas30 (n= 3) and Fas100 (n= 3). Means of both ventral
horns were calculated and the mean of all sections of each animal
was included in the final statistical analysis for both ChAT and
Iba1 cell numbers.
Statistical Analysis
For the analysis of electrophysiological quantifications between
two groups the unpaired Student’s t-test was applied. Multiple
group comparisons of immunohistological cell counts were done
by one-way ANOVA followed by Tukey’s post-hoc test. Behavioral
data were subjected to a multifactorial ANOVA analysis and
post-hoc Fisher’s test. Survival data were analyzed using Kaplan-
Meier survival fit analysis with Log-Rank tests for statistical
significance. Statistical analyses were performed using Statistica
10.0 (StatSoft, Hamburg, Germany) and Kyplot 2.0 (KyensLab
Inc, Tokyo, Japan). Data are represented as mean ± standard
error of the mean. Differences were considered significant with
∗P < 0.05; ∗∗P < 0.01; ∗∗∗P < 0.001.
RESULTS
Electrophysiological Alterations Indicate
Onset of Disease
In order to detect an early impairment of motor nerve function as
indicator for disease onset we examined wildtype and SOD1G93A
mice with electrophysiological methods at day of life 70 (d70) and
at day of life 100 (d100). At d70, the NCV of the sciatic nerve was
already significantly delayed in SOD1G93A animals if compared to
wildtype controls (SOD1WT: 30.63 ± 0.95 m/s; SOD1G93A: 24.07
± 1.10m/s) (Figure 1A). This NCV difference was also persistent
at d100 (SOD1WT: 26.31 ± 1.33 m/s; SOD1G93A: 20.72 ± 0.98
m/s) (Figure 1E). The CMAP at d70 was reduced in SOD1G93A
mice in comparison to SOD1WT [proximal CMAP: SOD1WT
9.10 ± 1.44 mV; SOD1G93A 5.17 ± 0.57 mV (Figure 1B); distal
CMAP: SOD1WT 12.10 ± 1.98 mV; SOD1G93A 8.78 ± 1.23
mV (Figure 1C)]. At d100, this difference increased even more
[proximal CMAP: SOD1WT 9.35 ± 0.93 mV; SOD1G93A 4.58
± 1.45 mV (Figure 1F); distal CMAP: SOD1WT 11.30 ± 1.61
mV; SOD1G93A 5.91± 1.73 mV (Figure 1G)]. The DML was not
significantly different at both time points [d70: SOD1WT 1.28 ±
0.09 ms; SOD1G93A 1.17 ± 0.07 ms (Figure 1D); d100: SOD1WT
1.22± 0.05 ms; SOD1G93A 1.33± 0.06 ms (Figure 1H)].
Weight Dynamics Are not Altered by
Fasudil Treatment in SOD1G93A Mice
Oral Fasudil treatment was initiated at d80 in symptomatic
SOD1G93A mice in two different dosages Fas30 and Fas100, both
in female and in male mice. Veh-treated SOD1G93A female and
male cohorts served as control. Among all cohorts differentiated
by gender, there were no significant differences in weight
dynamics. In females, the weight maximum for the Veh group
was reached at day 104 (19.54 ± 0.42 g), for the Fas30 group
at day 101 (19.98 ± 0.42 g) and for the Fas100 group at day 92
(19.86 ± 0.46 g). This corresponds to a mean maximum weight
FIGURE 1 | Electrophysiological analysis including NCV, CMAP and
DML of the sciatic nerve. Depicted are histograms for d70 (A–D) and for
d100 old (E–H) SOD1WT and SOD1 G93A mice (SOD1WT d70 n = 3, SOD1
G93A d70 n = 3, SOD1WT d100 n = 6, SOD1 G93A d100 n = 6). Bar
represents means ± SEM; *P < 0.05.; **P < 0.01.
gain from day 80 on in the Veh group of 1.94%, in the Fas30
group of 3.24% and in the Fas100 group of 3.90%. In males, the
weight maximum for the Veh group was reached at day 92 (25.26
± 0.48 g), for the Fas30 group at day 101 (24.89 ± 0.67 g) and
for the Fas100 group at day 95 (24.94 ± 0.43 g) corresponding
to a mean maximum weight gain from day 80 of 0.41% (Veh),
2.01% (Fas30) and 1.60% (Fas100). A progressive weight loss in
the female veh group was observed starting on day 104 and in
both female treatment groups starting on day 107. In contrast,
progressive weight loss in males started on day 92 in veh group,
on day 101 in the Fas30 group and on day 95 in the Fas100 group.
The overall dynamics of weight loss did not significantly differ in
female or male groups (Figure 2).
Progression of Neurological Symptoms
and Overall Survival Are not Modified by
Fasudil
We repeatedly performed neurological scoring over the entire
treatment period. Here, application of Fas30 or Fas100 did not
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FIGURE 2 | Weight dynamics in SOD1G93A transgenic mice orally treated with 30 mg/kg Fasudil (Fas30), 100 mg/kg Fasudil (Fas100) or with vehicle
(Veh). Depicted are female (Fas30 n = 14, Fas100 n = 15, Veh n = 14) (A,B) and male (Fas30 n = 11, Fas100 n = 12, Veh n = 12) (C,D) cohorts.
FIGURE 3 | Progression of neurological symptoms and disease duration in SOD1G93A mice treated with 30 mg/kg Fasudil (Fas30), 100 mg/kg Fasudil
(Fas100), or with vehicle (Veh) as control. Displayed are neurological scores and disease duration for female (Fas30 n = 14, Fas100 n = 15, Veh n = 14) (A,B)
and male (Fas30 n = 11, Fas100 n = 12, Veh n = 12) (C,D) cohorts.
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FIGURE 4 | Survival in SOD1G93A mice treated with 30 mg/kg Fasudil
(Fas30), 100 mg/kg Fasudil (Fas100), or with vehicle (Veh). Depicted is
the cumulative probability of survival of female (Fas30 n = 14, Fas100 n = 15,
Veh n = 14) (A) and male (Fas30 n = 11, Fas100 n = 12, Veh n = 12) (B)mice.
significantly modify the progression of clinical disease in both
female and male mice (Figures 3A,C). Similarly, the average
duration of disease was not significantly different between female
(Veh 45,57± 3,12 d; Fas30 41,57± 1,89 d; Fas100 41,60± 1,48 d)
and male (Veh 44,92± 3,31 d; Fas30 41,64± 3,54 d; Fas100 43,50
± 2,64 d) treatment groups (Figures 3B,D).
In the analysis of overall survival, the mean times of survival
were not significantly different in any treatment groups, neither
in female (Veh: 139.1 ± 2.7 days; Fas30 135.9 ± 1.8 days;
Fas100 136.7 ± 1.7 days) nor in male mice (Veh: 131.7 ±
2.8 days; Fas30 131.9 ± 1.8 days; Fas100 131.9 ± 2.1 days)
(Figure 4).
Fasudil Improves Motor Performance in
Male Mice
The evaluation of motor performance on a rotarod device reflects
both muscular strength and motor coordination. While female
mice showed similar results in all treatment groups, male mice
were significantly better in both Fas30 and Fas100 treatment
groups. The most significant differences to the control group
were observed at intermediate d110 (endurance on rotarod: Veh
81.64± 22.42 s; Fas30 133.91± 17.28 s; Fas100 153.92± 15.14 s)
(Figure 5).
FIGURE 5 | ROCK inhibition with Fasudil stabilizes motor performance
in SOD1G93A male mice. Displayed are mean durations on the rotarod of
female (Fas30 n = 14, Fas100 n = 15, Veh n = 14) (A) and male (Fas30 n =
11, Fas100 n = 12, Veh n = 12). (B) SOD1 G93A mice treated with 30 mg/kg
Fasudil (Fas30), 100 mg/kg Fasudil (Fas100), or with vehicle (Veh). Data
represent means ± SEM. * P< 0.05; **P < 0.01, ***P < 0.001.
Motoneuron Cell Survival and Microglial
Infiltration at Disease End-Stage
In order to evaluate underlying neuropathological alterations, we
quantified MN survival and MG cell infiltration in the anterior
horn of the lumbar spinal cord. There were no significant
differences in the number of ChAT-immunopositive MN in
both female (Veh 6.1 ± 0.53 MN/anterior horn; Fas30 5.39 ±
0.36 MN/anterior horn; Fas100 7.35 ± 0.29 MN/anterior horn)
and male mice (ChAT numbers Veh 7.15 ± 0.61 MN/anterior
horn; Fas30 8.43 ± 0.37 MN/anterior horn; Fas100 6.92 ± 0.29
MN/anterior horn) (Figure 6).
Iba1-immunopositive MG cells were found in the spinal cord
anterior horn at similar numbers in all treatment groups in
female (Veh 64.64 ± 2.65 MG/section; Fas30 56.52 ± 10.42
MG/section; Fas100 52.61 ± 7.53 MG/section) and male mice
(Veh 54.38 ± 4.54 MG/section; Fas30 59.22 ± 4.41 MG/section;
Fas100 56.91± 5.96 MG/section) (Figure 7).
DISCUSSION
ROCK inhibition by Fasudil has previously been shown to
exert neuroprotective, but also pro-regenerative and axon-
stabilizing effects in models of both ALS and PD (Tönges
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FIGURE 6 | Motoneuronal survival in the spinal cord in end-stage stage SOD1G93A transgenic mice. (A,B) Numbers of ChAT-immunopositive motoneurons
(MN) per section in the spinal cord anterior horn of female (Fas30 n = 3, Fas100 n = 3, Veh n = 3) and male (Fas30 n = 3, Fas100 n = 3, Veh) mice treated with 30
mg/kg Fasudil (Fas30), 100 mg/kg Fasudil (Fas100), or with vehicle (Veh). (C,D) Representative micrographs of ChAT-immunopositive MNs in the spinal cord anterior
horn of female (C) and male (D) mice. [ChAT/Cy3 (red), DAPI (blue)]. Bars represent means ± SEM. Scale bar: 100 µm.
et al., 2012, 2014). In addition, improvement of neurological
function or an increase of survival by ROCK inhibition was
recently reported in animal models of Huntington’s disease and
spinal muscular atrophy (Li et al., 2009; Bowerman et al., 2010,
2012). Treatment of presymptomatic SOD1G93A transgenic mice
with Fasudil starting at day of life 50 increased survival and
improved motor behavior in two independent studies (Takata
et al., 2013; Tönges et al., 2014). However, no treatment with
Fasudil has been performed so far in any of these models
in an advanced disease stage. Therefore, we performed a
treatment study in symptomatic SOD1G93A mice in order to
evaluate its therapeutic potential under clinically more relevant
conditions.
Disease Onset in the SOD1G93A Mouse
Model
Several parameters can be used to indicate disease onset in mouse
models of ALS. One parameter is the clinical phenotype of the
mice. It is well described that around d80 first clinical symptoms
start to appear with trembling of hind limbs (Turner and Talbot,
2008). Consequently, detection of trembling of hind limbs is
included in a commonly used neurological scoring system for
this mouse model (Miana-Mena et al., 2005) representing the
first disease stage (Weydt et al., 2003). In previous studies, we
had observed a decline from the healthy phenotype (score 4) to
the first disease stage (score 3) between d80 and d100 in both
male and female animals. At d100 nearly all animals had reached
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FIGURE 7 | Infiltration of microglial cells in the lumbar spinal cord anterior horn in end-stage stage SOD1G93A mice. (A,B) Numbers of
Iba1-immunopositive microglia (MG) per section in the spinal cord anterior horn of female (Fas30 n = 3, Fas100 n = 3, Veh) (A) and male (Fas30 n = 3, Fas100 n = 3,
Veh) (B) mice treated with 30 mg/kg Fasudil (Fas30), 100 mg/kg Fasudil (Fas100), or with vehicle (Veh). (C,D) Representative micrographs of Iba1-immunopositive MG
in spinal cord anterior horn of female (C) and male (D) mice. [Iba1/Cy3 (red), DAPI (blue)]. Bars represent means ± SEM. Scale bar: 100 µm.
disease onset (score 3) (Günther et al., 2014). Furthermore,
motor testing with a rotarod device resulted in a decline of
performance between d80 and d100. Applying a hanging wire
test we observed a decrease of muscle strength already after
d70 (Günther et al., 2014; Tönges et al., 2014). Concerning
these functional parameters it is important to note that male
mice are impaired earlier than females with regard to clinical
scoring and motor behavior. Taking into account the genetic
background of the animals, differences between females and
males in the SOD1G93A have been previously observed (Oliván
et al., 2015; Pfohl et al., 2015). While both, the C57BL/6 and
the B6SJL background, lead to delayed disease onset in females,
a prolonged survival was only observed in females with the
B6SJL background in comparison to their male counterparts
(Pfohl et al., 2015). Similar to previous reports, female animals
in our study had a prolonged survival time and a delayed decline
in motor performance as compared to their male counterparts
(Miana-Mena et al., 2005; Alves et al., 2011; Mancuso et al.,
2012; Pfohl et al., 2015). Another quantitative method to assess
initiation or progression of disease is the examination based on
electrophysiological measurements, which was used in this study
and represents also an important diagnostic tool for human ALS
(Brooks et al., 2000). Considerable differences between SOD1WT
and SOD1G93A have recently been reported in a previous study
on time point d100 and additional comprehensive evaluations of
electrophysiological measurements have been done (Alves et al.,
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2011; Mancuso et al., 2012; Tönges et al., 2014). Mancuso et al.
determined onset of disease between 70 and 90 days of age in the
SOD1mousemodel which was associated with CMAP alterations
of the tibialis anterior muscle suggesting that electrophysiological
measures can be a marker for disease onset (Mancuso et al.,
2012). In our own electrophysiological analysis we also used
neurographic measurements and could detect deteriorations in
CMAPs and a significant deceleration of NCVs compared to
SOD1WT already on d70. In line with progressive disease, CMAPs
deteriorated and became significantly reduced at d100. These
results confirm a disease onset in electrophysiological terms at
around d70 and the presence of progressive disease until d100
in SOD1G93A animals. In order to define a distinct starting point
for treatment in our study we then chose d80 which additionally
incorporates interindividual variances in SOD1G93A mice and
thus represent a clear time point of manifest disease.
Fasudil Improves Motor Performance in
Male SOD1G93A Mice
Fasudil treatment was thus started at d80 in two different
concentrations (Fas30 and Fas100) and was clinically well
tolerated. The weight course was comparable to the Veh group.
In our treatment paradigm, Fasudil treatment did not prolong
survival and we could not observe a statistically relevant benefit
in the graded clinical examination. However, if we applied
more sensitive examination methods for motor strength and
coordination with rotarod testing, male animals showed a benefit
from treatment with both dosages.
Others and our own group had found a moderate protection
of spinal cord MN in an intermediate analysis on day 100 with
identical dosages of Fasudil if treatment was started already at
a presymptomatic stage at day 50 (Takata et al., 2013; Tönges
et al., 2014). However, the histological analysis in endstage
animals did not reveal significant differences of MN survival
or in MG infiltration between the groups. In the symptomatic
treatment study from day 80, we similarly did not detect clear
ameliorations such as an increased motoneuron survival on the
neuropathological level. This may be due to an only functional
improvement of motoneurons, which, however, was too small or
unstable to transfer to a persistant cellular change.
Another reason for the rather small treatment effect observed
in our study is most probably the advanced pathology that is
already present at the time, when animals become clinically
symptomatic (Turner and Talbot, 2008). It is also known, that
progression of disease in the SOD1G93A mouse model is rather
rapid and one could hypothesize that a more slowly progressing
disease model would yield more favorable results. Many groups
have performed therapeutic pilot studies in the SOD1G93A mouse
model in a clinically presymptomatic stage between 30 and 60
days of age, long before clinical symptoms become obvious
(Turner and Talbot, 2008), but this strategy is insufficient
if no verification with a treatment after symptom onset is
performed.
Of interest, significant, but overall only moderate therapeutic
effects were found exclusively in male mice in this study.
Gender specific effects have also been reported in the Y-27632
presymptomatic treatment study (Günther et al., 2014) and
differences in the disease course between male and female mice
were previously described (Alves et al., 2011; Oliván et al., 2015;
Pfohl et al., 2015). Ovariectomy in the SOD1G93A mouse model
leads to a decrease in survival time and makes female mice
progress almost as fast as male mice. In line with this finding,
estrogen treatment can counteract the effects of ovariectomy
(Groeneveld et al., 2004; Choi et al., 2008). Similarly, ovariectomy
in the MPTP model of Parkinson’s disease leads to an increase
of ROCK activity and treatment with either estrogen or a
ROCK inhibitor could inhibit MPTP-induced dopaminergic
cell death. Furthermore, ROCK activity was less increased
in ovariectomized MPTP mice when treated with estrogen
(Rodriguez-Perez et al., 2013). In analogy, ROCK activity could
be higher in male mice in advanced disease and therefore the
application of Fasudil could have been more successful in male
mice in our study.
In multiple other neurodegenerative disease models, ROCK
inhibitors and particularly Fasudil showed very promising
results. In the MPTP model of Parkinson’s disease Fasudil
significantly protected both dopaminergic neurons and its
axonal nigrostriatal terminals, restoring striatal neurotransmitter
levels and attenuating behavioral deficits (Tönges et al., 2012).
Furthermore, Fasudil attenuated alpha-synuclein aggregation
in vitro and in vivo in a genetic model of Parkinson’s disease
(Tatenhorst et al., 2016). In a Drosophila model of tauopathy,
Fasudil suppressed the rough eye phenotype and mitigated
pathogenic tau levels by inducing autophagic pathways (Gentry
et al., 2016). Furthermore, significant therapeutic effects were also
observed in a mouse model of Huntington’s disease, both with
Y-27632 and Fasudil treatment (Li et al., 2009, 2013), and in a
model of spinal muscle atrophy, a condition with high similarity
to ALS. Here the clinical progression was attenuated by Y-27632
and Fasudil (Bowerman et al., 2010, 2012).
In a translational perspective, Fasudil combines several
highly promising features. It is an already licensed drug,
which has a long-standing clinical history with several tens
of thousands of patients treated, demonstrating a favorable
safety-profile (Suzuki et al., 2007). Its pharmacokinetics is
characterized by excellent solubility in water, sufficient uptake
into the CNS and no major interactions with Cytochrome
P450 enzymes. The fact that Fasudil is effective in several
disease models, which all combine similar pathomechanisms
of neurodegeneration, reaffirms its potential for a drug-
repositioning approach.
CONCLUSION
The therapeutic application of the ROCK inhibitor Fasudil in
an advanced symptomatic disease stage in SOD1G93A ALS mice
resulted in significant improvements of motor function, but
was less effective when compared to paradigms, when animals
were treated before clinical symptom onset. However, given
the advanced pathology at first symptom onset in this model,
the ability to beneficially modify motor function is remarkable.
Although the neuroprotective potential of Fasudil in ALS is best
if applied before clinical symptom onset, our study supports
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the testing of Fasudil in clinical trials including patients at the
earliest-possible disease stage.
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